(Reuters) - U.S. drugmaker Pfizer Inc PPE.N is considering options, including a sale of its women’s health portfolio, Bloomberg reported on Thursday, citing sources familiar with the matter.
A sale of the division, which has annual sales of about $1.2 billion, could fetch about $2 billion and draw bids from both private equity firms and rival pharmaceutical companies, Bloomberg reported here
Pfizer did not immediately respond to Reuters request for comment.
Allergan Plc (AGN.N) said in May it planned to sell off its women’s health and infectious disease units, to focus on its core businesses.
Reporting by Manogna Maddipatla in Bengaluru; Editing by Shailesh Kuber